Drugs & Targets Pralsetinib receives FDA approval for lung cancer with RET gene fusions September 11, 2020Vol.46 No.34
Drugs & Targets Oncomine Dx Target Test receives FDA approval as first NGS-based companion diagnostic for RET fusion + NSCLC September 11, 2020Vol.46 No.34
Drugs & Targets FDA issues alert about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer September 11, 2020Vol.46 No.34
Drugs & Targets Oncocyte receives final pricing decision for DetermaRx Molecular Test for lung cancer from CMS September 11, 2020Vol.46 No.34
Drugs & Targets MD Anderson, Xencor collaborate on investigational XmAb drug candidates September 11, 2020Vol.46 No.34
Clinical Roundup JNCCN study sheds light on multi-organ adverse events from immunotherapy September 11, 2020Vol.46 No.34
Clinical Roundup City of Hope scientists combine oncolytic virus and CAR T in solid tumors September 11, 2020Vol.46 No.34
Clinical Roundup Phase II study of Tabrecta shows positive ORR for NSCLC September 11, 2020Vol.46 No.34
In Brief Justin Leung receives $1.9 million in funds to research DNA damage response September 11, 2020Vol.46 No.34
